Company news
Appili Therapeutics Inc Class A (TSX:APLI) news
Appili Therapeutics Inc Class A news releases on 6ix. Latest, Sep 29, 2026: Appili Therapeutics Announces Transfer to NEX
Press releases & updates
Appili Therapeutics Announces Transfer to NEX
September 29, 2026
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
August 14, 2026
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
July 3, 2026
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
June 26, 2026
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
March 30, 2026
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
February 18, 2026
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
February 12, 2026
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
December 18, 2025
The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID
December 15, 2025
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
November 13, 2025
The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID
November 12, 2025
Appili Therapeutics Announces Proposed Non-Brokered Private Placement
November 5, 2025
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
October 22, 2025
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
October 1, 2025
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
September 24, 2025
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
September 23, 2025
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
September 23, 2025
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
September 9, 2025
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
August 14, 2025
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
August 6, 2025
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
June 25, 2025
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
May 30, 2025
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
May 19, 2025
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
May 1, 2025
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®(TM)
April 28, 2025
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
April 28, 2025
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
April 2, 2025
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
April 2, 2025
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
March 28, 2025
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
March 24, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
March 18, 2025
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
February 14, 2025
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
November 20, 2024
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek 2024
October 18, 2024
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
October 17, 2024
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
October 10, 2024
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
August 13, 2024
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
June 25, 2024
IIROC Trade Resumption - APLI
May 18, 2022
IIROC Trading Halt - APLI
May 17, 2022
AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics
September 29, 2021
Appili Therapeutics Virtually Opens The Market
September 18, 2020
IIROC Trading Resumption - APLI
June 4, 2020
Appili Therapeutics Inc. Opens the Market
July 3, 2019